In biotech, when you hear that a drug's peak sales estimates hover around $200 million, usually you shrug. But for a stock like Amicus Therapeutics (NASDAQ:FOLD), with a market cap of under $300 million, suddenly $200 million in potential sales looks like a big deal.
Amicus announced yesterday that it would be reporting data from its phase 3 study (titled "Study 012") for Migalast HCL for Fabry Disease sometime in third quarter. And today shareholders got even better news, as analysts moved their price targets on the stock, reflecting increasing market optimism that this drug will perform well.
But is the stock a good investment? In the video below, Motley Fool health care analysts Michael Douglass and David Williamson give their two cents on Amicus.
David Williamson, Michael Douglass, and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.